Triptorelin GnRHCheck methods and identity
How an endometriosis study tested two triptorelin preparations
3 numbered sourcesSource years 2025, 2026
Peptides consist of short amino-acid chains held by peptide bonds, and some can alter how much of another hormone the body makes. Triptorelin is a synthetic ten-amino-acid agonist of the receptor for gonadotropin-releasing hormone, or GnRH. Sustained exposure can lower ovarian estrogen production. A 2026 study in China asked whether an acetate microsphere preparation, in which the drug is carried in small particles, suppressed estradiol about as well as an established triptorelin acetate comparator in people with endometriosis. [1, 2]
The double-blind phase III trial enrolled 392 patients across 47 centers. Each group received an active triptorelin formulation. The main outcome was the proportion whose estradiol fell below the study threshold. At the primary assessment, about 97 percent of participants included in the analysis met that endpoint with the microspheres and about 98 percent did with the comparator. The researchers used a non-inferiority design, which sets the maximum acceptable difference before the trial. The uncertainty around the observed difference stayed within that predefined margin. [1]
Participants in both groups reported lower scores for menstrual pain and pelvic pain outside menstruation compared with their own starting scores, with no statistically clear difference between groups. The proportion reporting adverse drug reactions was also similar. The study found a difference in how soon menstruation returned after treatment ended. That is a distinct outcome from estradiol suppression, and the main result applies to the hormone outcome that the investigators chose in advance. [1]
Comparing two active preparations answers a question about how they perform relative to each other. It leaves the size of any difference versus no treatment outside this experiment. The study was conducted with specific products in China. The two U.S. product labels cited here list advanced prostate cancer and central precocious puberty as their respective approved uses. [1, 2, 3]
Sources
Original works cited in this article. Links open the external record in a new tab.
